尼妥珠单抗联合放化疗治疗局部晚期头颈部恶性肿瘤的临床效果  

Clinical Effect of Nituzumab Combined with Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Malignancies

作　　者：张开国[1] 张芬[1] 蒋鹏[2] ZHANG Kaiguo;ZHANG Fen;JIANG Peng(Department of OncologyⅢ,Tengzhou Central People's Hospital,Tengzhou,Shandong Province,277500 China;Department of OncologyⅡ,Tengzhou Central People's Hospital,Tengzhou,Shandong Province,277500 China)

机构地区：[1]滕州市中心人民医院肿瘤三科,山东滕州277500 [2]滕州市中心人民医院肿瘤二科,山东滕州277500

出　　处：《系统医学》2024年第9期187-190,共4页Systems Medicine

摘　　要：目的分析局部晚期头颈部恶性肿瘤实施尼妥珠单抗+放化疗治疗的价值。方法选取滕州市中心人民医院于2021年11月—2022年11月收治的72例局部晚期头颈部恶性肿瘤患者为研究对象,依掷骰子分为基础组和综合组,每组36例,基础组行放化疗,综合组加用尼妥珠单抗,对比两组的近远期疗效和不良反应。结果综合组的临床缓解率(58.33%),和临床控制率(88.89%)均高于基础组(30.56%、66.67%),差异有统计学意义(χ^(2)=5.625、5.143,P=0.018、0.023)。随访1年后综合组生存率(80.56%)高于基础组(58.33%),差异有统计学意义(P<0.05)。两组各项不良反应反应率比较,差异无统计学意义(P>0.05)。结论放化疗时辅以尼妥珠单抗治疗不会增加不良反应,且能维持高缓解率和控制率,提升远期生存率,适用于局部晚期头颈部恶性肿瘤患者。Objective To analyze the value of nituzumab plus chemoradiotherapy in the treatment of locally advanced head and neck malignancies.Methods A total of 72 patients with local advanced stage of head and neck malignant tumors who were admitted in Tengzhou Central People's Hospital from November 2021 to November 2022 were taken as study objects.They were divided into basic group and comprehensive group with 36 cases in each group by rolling dice.The basic group received chemoradiation and chemotherapy,while the comprehensive group received nituzumab based on basic group.The short-term and long-term curative effects and adverse reaction were compared between two groups.Results The clinical remission rate(58.33%)and clinical control rate(88.89%)in comprehensive group were higher than those of the basic group(30.56%,66.67%),and the differences were statistically significant(χ^(2)=5.625,5.143,P=0.018,0.023).The survival rate of the comprehensive group was 80.56%,which was higher than that of the basic group(58.33%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion Treatment with nituzumab during chemoradiotherapy does not induce more adverse reaction,and can maintain a high remission rate and control rate,as well as improve long-term survival rate,which is suitable for patients with locally advanced head and neck malignancies.

关 键 词：恶性肿瘤 头颈部 近远期疗效 尼妥珠单抗 不良反应 

分 类 号：R4[医药卫生—临床医学]